Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer

C. A. Carter, A. Rajan, C. Keen, E. Szabo, S. Khozin, A. Thomas, C. Brzezniak, U. Guha, L. A. Doyle, S. M. Steinberg, L. Xi, M. Raffeld, Y. Tomita, M. J. Lee, S. Lee, J. B. Trepel, K. L. Reckamp, S. Koehler, B. Gitlitz, R. SalgiaDavid R Gandara, E. Vokes, G. Giaccone

Research output: Contribution to journalArticle

41 Scopus citations

Abstract

Background: KRAS mutations in NSCLC are associated with a lack of response to epidermal growth factor receptor inhibitors. Selumetinib (AZD6244; ARRY-142886) is an oral selective MEK kinase inhibitor of the Ras/Raf/MEK/ERK pathway. Patients andmethods: Advanced nonsmall-cell lung cancer (NSCLC) patients failing one to two prior regimens underwent KRAS profiling. KRAS wild-type patients were randomized to erlotinib (150 mg daily) or a combination of selumetinib (150 mg daily) with erlotinib (100 mg daily). KRAS mutant patients were randomized to selumetinib (75 mg b.i.d.) or the combination. The primary end points were progression-free survival (PFS) for the KRAS wild-type cohort and objective response rate (ORR) for the KRAS mutant cohort. Biomarker studies of ERK phosphorylation and immune subsets were carried out. Results: From March 2010 to May 2013, 89 patients were screened; 41 KRAS mutant and 38 KRAS wild-type patients were enrolled. Median PFS in the KRAS wild-type arm was 2.4 months [95% confidence interval (CI) 1.3-3.7] for erlotinib alone and 2.1 months (95% CI 1.8-5.1) for the combination. The ORR in the KRAS mutant group was 0% (95% CI 0.0% to 33.6%) for selumetinib alone and 10% (95% CI 2.1% to 26.3%) for the combination. Combination therapy resulted in increased toxicities, requiring dose reductions (56%) and discontinuation (8%). Programmed cell death-1 expression on regulatory T cells (Tregs), Tim-3 on CD8+ T cells and Th17 levels were associated with PFS and overall survival in patients receiving selumetinib. Conclusions: This study failed to show improvement in ORR or PFS with combination therapy of selumetinib and erlotinib over monotherapy in KRAS mutant and KRAS wild-type advanced NSCLC. The association of immune subsets and immune checkpoint receptor expression with selumetinib may warrant further studies.

Original languageEnglish (US)
Article numbermdw008
Pages (from-to)693-699
Number of pages7
JournalAnnals of Oncology
Volume27
Issue number4
DOIs
StatePublished - Apr 1 2016

Keywords

  • EGFR
  • Erlotinib
  • KRAS
  • MEK
  • Nonsmall-cell lung cancer
  • Selumetinib

ASJC Scopus subject areas

  • Medicine(all)
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Carter, C. A., Rajan, A., Keen, C., Szabo, E., Khozin, S., Thomas, A., Brzezniak, C., Guha, U., Doyle, L. A., Steinberg, S. M., Xi, L., Raffeld, M., Tomita, Y., Lee, M. J., Lee, S., Trepel, J. B., Reckamp, K. L., Koehler, S., Gitlitz, B., ... Giaccone, G. (2016). Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Annals of Oncology, 27(4), 693-699. [mdw008]. https://doi.org/10.1093/annonc/mdw008